MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Celgene Company Profile (NASDAQ:CELG)

Consensus Ratings for Celgene (NASDAQ:CELG) (?)
Ratings Breakdown: 4 Hold Rating(s), 23 Buy Rating(s)
Consensus Rating:Buy (Score: 2.85)
Consensus Price Target: $143.52 (47.53% upside)

Analysts' Ratings History for Celgene (NASDAQ:CELG)
Show:
DateFirmActionRatingPrice TargetActions
6/27/2016Canaccord GenuityReiterated RatingBuy$156.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/23/2016JMP SecuritiesReiterated RatingBuy$152.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016BarclaysReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Bank of AmericaReiterated RatingBuy$125.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016BMO Capital MarketsReiterated RatingBuy$132.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016BTIG ResearchDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/25/2016William BlairReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2016Jefferies GroupReiterated RatingBuy$140.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2016ArgusReiterated RatingBuy$155.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Credit SuisseReiterated RatingOutperform$140.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2016Leerink SwannReiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/29/2016Morgan StanleyReiterated RatingHold$127.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/28/2016Piper JaffrayReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/28/2016Raymond JamesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/28/2016SunTrustReiterated RatingBuy$145.00 -> $147.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/28/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/26/2016Robert W. BairdReiterated RatingBuy$162.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Boost Price TargetMarket Outperform$147.00 -> $152.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Citigroup Inc.Initiated CoverageBuy$130.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman SachsLower Price Target$90.00 -> $83.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/29/2016RBC CapitalLower Price TargetOutperform$150.00 -> $135.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2016Wells FargoReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/14/2016Standpoint ResearchInitiated CoverageBuy$130.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/25/2015NomuraReiterated RatingBuy$165.00 -> $167.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/15/2015Deutsche BankBoost Price TargetBuy$160.00 -> $175.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/2/2015Sanford C. BernsteinReiterated RatingBuy$154.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/30/2015S&P Equity ResearchReiterated RatingStrong-BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Celgene (NASDAQ:CELG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/21/2016        
4/28/2016Q116$1.29$1.32$2.59 billion$2.51 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/28/2016Q415$1.22$1.18$2.54 billion$2.54 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315$1.22$1.23$2.40 billion$2.33 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/23/2015Q215$1.08$1.23$2.24 billion$2.28 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115$1.06$1.07$2.11 billion$2.08 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/29/2015Q414$0.99$1.01$2.08 billion$2.09 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/23/2014Q314$0.95$0.97$1.96 billion$1.96 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/24/2014Q214$0.89$0.90$1.85 billion$1.87 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/24/2014Q114$1.65$1.67$1.77 billion$1.71 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/30/2014Q413$1.54$1.51$1.72 billion$1.76 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/24/2013Q313$1.54$1.56$1.64 billion$1.67 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2013Q2 2013$1.44$1.52$1.54 billion$1.56 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/25/2013Q1 2013$1.35$1.37$1.47 billion$1.43 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/24/2013Q4 2012$1.31$1.32$1.45 billion$1.42 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/25/2012$1.26$1.29ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/26/2012$1.19$1.22ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/26/2012$1.13$1.08ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/26/2012$1.06$1.05ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2011$0.95$1.02ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2011$0.85$0.89ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2011$0.80$0.83ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/27/2011$0.73$0.73ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Celgene (NASDAQ:CELG)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$1.09$1.09$1.09
Q2 20162$1.21$1.26$1.24
Q3 20162$1.28$1.31$1.30
Q4 20162$1.36$1.37$1.37
(Data provided by Zacks Investment Research)
Dividend History for Celgene (NASDAQ:CELG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Celgene (NASDAQ:CELG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/20/2016Robert J HuginInsiderSell75,000$100.16$7,512,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016Gilla KaplanDirectorSell15,967$101.84$1,626,079.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016Michael W BonneyDirectorBuy2,000$103.01$206,020.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/22/2016James J LoughlinDirectorSell2,100$104.12$218,652.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015Ernest MarioDirectorSell40,000$119.36$4,774,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2015Michael D CaseyDirectorSell20,000$122.11$2,442,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/21/2015Gilla KaplanDirectorSell14,464$110.62$1,600,007.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2015Gilla KaplanDirectorSell15,000$122.45$1,836,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Michael D. CaseyDirectorSell15,000$121.76$1,826,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Thomas O DanielInsiderSell30,156$120.78$3,642,241.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2015Gilla KaplanDirectorSell15,000$111.74$1,676,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2015Michael D CaseyDirectorSell15,000$111.18$1,667,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2015Gilla KaplanDirectorSell15,000$122.89$1,843,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/6/2015Mark J AllesInsiderSell117,099$120.68$14,131,507.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015Lawrence V SteinInsiderSell26,666$120.01$3,200,186.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Gilla KaplanDirectorSell45,536$113.47$5,166,969.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014Gilla KaplanDirectorSell15,000$118.20$1,773,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Robert J HuginInsiderSell158,000$106.68$16,855,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/27/2014Ernest MarioDirectorSell100,000$102.85$10,285,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/24/2014Michael D CaseyDirectorSell15,000$102.94$1,544,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014Gilla KaplanDirectorSell30,000$93.73$2,811,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/4/2014Perry A KarsenInsiderSell39,104$87.55$3,423,555.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/25/2014Richard W BarkerDirectorSell17,600$87.03$1,531,728.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Perry KarsenInsiderSell11,922$146.78$1,749,911.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2014Michael CaseyDirectorSell12,770$162.33$2,072,954.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2014Ernest MarioDirectorSell13,500$151.87$2,050,245.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2013Lawrence SteinInsiderSell12,062$168.19$2,028,707.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/25/2013Carrie Smith CoxDirectorSell18,750$157.67$2,956,312.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2013Gilla KaplanDirectorSell15,000$143.92$2,158,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2013Thomas DanielInsiderSell32,263$137.06$4,421,966.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/2/2013Perry A KarsenInsiderSell93,008$146.50$13,625,672.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/30/2013Robert J HuginInsiderSell68,087$123.58$8,414,191.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2013Ernest MarioDirectorBuy1,000$123.72$123,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013Thomas O DanielInsiderSell32,959$124.91$4,116,908.69View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Celgene (NASDAQ:CELG)
DateHeadline
06/28/16 07:37 PMCelgene's Phase 3 Study Of REMARC Likely To Be Successful, Says Jefferies
06/28/16 05:30 PMWhich Biotechnology Companies Could Benefit from Brexit? -
06/28/16 02:29 PMA Look At Concert Pharmaceuticals
06/28/16 02:29 PMReport delivers insight into the hepatocellular carcinoma pipeline landscape and therapeutics under development market review 2016
06/28/16 11:01 AM5 Top Biotechs Where Future Multi-Billion Dollar Drug Pipelines are Valued Almost at Zero -
06/28/16 09:55 AMBiotechs: After Brexit, Buy the Stocks and Get the Pipelines For Free -
06/27/16 08:42 PMThe Largest Drug Pipelines Will Surprise You -
06/27/16 07:45 AMHow Does Brexit Impact Healthcare Stocks?
06/27/16 07:45 AMFour Strategies For Creating Value In Life Sciences
06/25/16 03:04 PMHow The Gig Economy Is Impacting The Life Sciences Industry
06/25/16 07:02 AMCancer survivors celebrate with Dr. Daniel Moriarity of Chatham Township
06/24/16 05:12 AMCelgene Corporation (CELG) is Trading Higher on Unusual Volume for June 22
06/23/16 11:09 AMCelgene takes aim at cancer innovation with new US research consortium
06/23/16 11:09 AMCelgene puts up $50 million to partner with four NCI cancer centers
06/22/16 08:25 PMCelgene Corporation (CELG) is Trading Lower on Unusual Volume for June 21
06/22/16 08:25 PMCelgene Inks $50M in Cancer Collaborations with Four Institutions
06/22/16 03:16 PMJohns Hopkins joins partnership to discover, develop new cancer treatments
06/22/16 03:15 PMCelgene : Landmark cancer research consortium announced
06/22/16 11:37 AMWorst Is Yet to Come for Celgene? -
06/22/16 10:38 AMPharma stocks are soaring for the first time in weeks because something didn't happen -
06/22/16 07:53 AMCelgene Inks $50M in Cancer Collaborations with 4 Institutions
06/22/16 07:53 AMCelgene, NCI Cancer Centers-consortium To Focus On Accelerating Drug Development
06/22/16 07:53 AMCelgene (CELG) Enters Collaboration Agreements with Four Major Academic Institutions
06/22/16 07:53 AMFour NCI Cancer Centers Announce Landmark Research Consortium and Collaborations with Celgene
06/22/16 07:25 AMBiotechs Highlight Jefferies 4 Top Growth Stocks to Buy -
06/21/16 01:32 PMCelgene: Is It a Buy? -
06/20/16 09:29 AMCelgene: More Than a One-Drug Wonder - Barron's
06/20/16 09:29 AMPut trade follow downtrend in Celgene
06/19/16 02:59 PMBarron's Picks And Pans: Celgene, Square, Delphi Automotive And More
06/18/16 02:59 PMCelgene: More Than a One-Drug Wonder
06/18/16 01:19 PMBetter Buy: Ziopharm Oncology, Inc. vs. Celgene - Both are making big bets on the immune system's ability to attack cancer, but which is the better buy?
06/17/16 11:01 PM[$$] Celgene: More Than a One-Drug Wonder -
06/17/16 11:05 AMOne Direction, Separate Leadership Positions Prove Vital to Celgene’s Success
06/17/16 09:03 AMDigging Below the Surface: Here's What Celgene's New Stock Buyback Really Implies -
06/16/16 08:30 PMCelgene Joins DNDi's 'Drug Discovery Booster' - Pharmaceutical Processing
06/16/16 03:06 PMCelgene stock edges higher amid $3 billion buyback announcement
06/16/16 03:06 PMCelgene Is ‘Best Large-Cap Growth Story in Biotech’
06/16/16 03:06 PMCelgene Boosts Repurchase Program by $3 Billion
06/16/16 01:40 PMOne Direction, Separate Leadership Positions Prove Vital to Celgene's Success -
06/15/16 06:02 PMCramer: Here's What's Really Behind This Hatred for Biotechs -
06/15/16 03:11 PMCelgene joins DNDi's 'Drug Discovery Booster' - EurekAlert (press release)
06/15/16 03:11 PMStocks to Watch: Dynegy, Celgene and Progressive - Wall Street Journal (blog)
06/15/16 10:31 AMWhy Best Buy, Celgene, and Three Other Stocks Are Making Headlines Today -
06/15/16 07:56 AMCELGENE CORP /DE/ : Other Events (form 8-K)
06/15/16 07:56 AMBRIEF-Celgene announces additional $3 bln share repurchase authorization
06/15/16 07:56 AMCelgene Board Authorizes Additional $3.0 Bln Stock Repurchase - Quick Facts
06/15/16 07:43 AMCelgene (CELG) Stock Higher on Share Repurchase Program -
06/15/16 07:38 AM[$$] Celgene Ups Repurchase Program by $3 Billion -
06/15/16 06:49 AMCelgene Announces Additional $3 Billion Share Repurchase Authorization - [at noodls] - SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that during its June meeting the Company's Board of Directors authorized the repurchase of up to an additional $3.0 billion ...
06/15/16 06:37 AMCelgene authorizes $3 billion open-ended buyback program -
About Celgene

Celgene logoCelgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company's primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company's clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CELG
  • CUSIP: 15102010
Key Metrics:
  • Previous Close: $97.28
  • 50 Day Moving Average: $102.29
  • 200 Day Moving Average: $104.58
  • P/E Ratio: 47.32
  • P/E Growth: 0.76
  • Market Cap: $75.35B
  • Current Quarter EPS Consensus Estimate: $5.68 EPS
Additional Links:
Celgene (NASDAQ:CELG) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha